Ginkgo Bioworks CEO wants to build the Amazon Web Services of biotech
By Vikash in Business
Updated 3 years ago
The Boston-based synthetic biology leader Ginkgo Bioworks will go public via the SPAC company Soaring Eagle Acquisition. Why it matters: The deal — one of the biggest yet in the SPAC space — values Ginkgo at an implied $15 billion, and will channel funding into CEO Jason Kelly's plans to turn the company into the Amazon Web Services (AWS) of synthetic biology.
